"Dipyridamole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
| Descriptor ID |
D004176
|
| MeSH Number(s) |
D03.383.742.175
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dipyridamole".
Below are MeSH descriptors whose meaning is more specific than "Dipyridamole".
This graph shows the total number of publications written about "Dipyridamole" by people in this website by year, and whether "Dipyridamole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dipyridamole" by people in Profiles.
-
Barlas RS, Loke YK, Mamas MA, Bettencourt-Silva JH, Ford I, Clark AB, Bowles KM, Metcalf AK, Potter JF, Myint PK. Effect of Antiplatelet Therapy (Aspirin?+?Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke. Am J Cardiol. 2018 09 15; 122(6):1085-1090.
-
Fenimore GS. Evaluating CAD with a pharmacologic stress test. Nursing. 2010 May; 40(5):51-2.
-
Usman MH, Notaro LA, Nagarakanti R, Brahin E, Dessain S, Gracely E, Ezekowitz MD. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol. 2009 Apr 15; 103(8):1107-12.
-
Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008 Mar; 93(3):331-5.
-
Jamieson DG, Parekh A, Ezekowitz MD. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther. 2005 Sep; 10(3):153-61.
-
Borges-Neto S, Tuttle RH, Shaw LK, Smith WT, Jain D, Coleman RE, Whellan D. Outcome prediction in patients at high risk for coronary artery disease: comparison between 99mTc tetrofosmin and 99mTc sestamibi. Radiology. 2004 Jul; 232(1):58-65.